Ulrich Medical POLITICAL

Target: ulrich GmbH & Co. KG, trading as ulrich medical. ¹

Research date: 28 October 2026.

Legal identity: The company identifies ulrich GmbH & Co. KG as the German operating entity and ulrich Verwaltungs GmbH as its personally liable partner. ²

Corporate Communications & Public Stance

Official communications

The company’s published corporate mission emphasizes medical technology, patient care, product quality and manufacturing in Germany; its corporate website identifies healthcare professionals and medical institutions as its principal audience. ³

The company’s public news archive contains announcements concerning medical products, business growth, workforce matters, professional education and sponsorships, but no public evidence identified of an official statement specifically addressing Israel’s military operations in Gaza, Palestinian civilian harm or Israeli settlements within the material reviewed as of 28 October 2026. ⁴

Comparative public posture

On 25 September 2025, ulrich GmbH & Co. KG announced sponsorship of the German women’s national sitting volleyball team, describing the initiative as support for inclusion and equal opportunities. ⁵

On 6 October 2026, ulrich GmbH & Co. KG announced its presenting-partner role in Nursing Day, held on 30 September 2026 with ratiopharm ulm and University Hospital Ulm, and published a statement from CEO Friedrich von Rechteren expressing appreciation for healthcare professionals. ⁶

The reviewed public news archive does not establish a dated company statement on Ukraine, Black Lives Matter or another comparable armed conflict against which a specific Israel-Palestine communications disparity can be verified; no public evidence identified. ⁴

Market framing

The company describes itself as internationally active and reports that it distributes through specialist partners in more than 50 export countries, while maintaining direct operations in Germany, the United States, France and Spain. ⁷

Gil Medical Group, an Israeli medical-device distributor, publicly identifies Ulrich as a commercial partner on its own website; the listing uses standard manufacturer-partner presentation and contains no identified statement concerning Israeli military or settlement policy. ⁸

Communication act record

Acting entity: ulrich GmbH & Co. KG; recipient: German women’s national sitting volleyball team; channel: corporate announcement on ulrichmedical.com and proposed company social-media coverage; earliest documented observation: 25 September 2025; latest verified observation: corporate page available in October 2026; declared sponsorship term: four years; status: announced as continuing toward 2028, without independently verified payment schedules; audience: website readers and the company’s social-media audience, whose reach was not established. ⁵

Acting entity: ulrich GmbH & Co. KG; beneficiaries: nursing professionals and healthcare institutions in the Ulm region; channel: ulrichmedical.com and a public sporting event; event date: 30 September 2026; announcement date: 6 October 2026; status: event completed, corporate marketing relationship separately stated to have begun for the 2026–2027 season; geographic audience: Ulm-region event attendees and public website readers; exact communication reach unknown. ⁶

Operations in Occupied or Contested Territories

Israeli commercial presence

Gil Medical Ltd is identified in a 2021 Japan External Trade Organization medical-device industry report as an Israeli distributor located in Petach Tikva, with Ulrich among its represented manufacturers. ⁹

Gil Medical Group’s publicly accessible website continues to identify Ulrich as a partner in October 2026. ⁸

Gil Medical’s orthopedic products page identifies Ulrich specifically with spinal implants and fixation products, establishing the category of Ulrich equipment represented by the intermediary. ¹⁰

Gil Medical states that it has operated within the Israeli medical sector since 1972 and provides nationwide distribution and customer support. ¹¹

The manufacturer’s own 2026 global locations page lists Germany, the United States, France and Spain as its corporate locations and describes the use of exclusive specialist distributors in export markets. ⁷

Ministry of Defense customer relationship

The 2021 JETRO profile lists Gil Medical Ltd’s principal customers as the Ministry of Defense and private hospitals, while separately identifying Ulrich among the manufacturer’s represented brands. ⁹

The JETRO document does not identify which Gil Medical products were purchased by the Ministry of Defense, and no Ulrich-specific ministry contract, tender, product delivery or transaction was established from the reviewed company and distributor materials. ⁹

Occupied Palestinian Territory

Gil Medical’s current corporate and orthopedic product pages identify Israeli distribution and Ulrich products but do not identify a specific Ulrich installation, sale, delivery or service contract in an Israeli settlement, occupied East Jerusalem or the occupied West Bank; no public evidence identified within those records. ¹⁰

The company’s published global locations page does not identify an Ulrich-owned site in the occupied territories; no public evidence identified in that corporate locations disclosure. ⁷

Legal and regulatory scrutiny

The reviewed company compliance and corporate materials do not document an Israel-Palestine-related regulatory finding, legal proceeding or settlement-related sanction against ulrich GmbH & Co. KG; no public evidence identified in those materials. ¹²

Civil-society and boycott campaigns

The reviewed corporate news archive and Gil Medical partner documentation do not identify a named boycott or divestment campaign directed specifically against ulrich GmbH & Co. KG, or a corporate response to one; no public evidence identified in those records. ⁴

Territorial and commercial act records

Acting entity: Gil Medical Ltd; commercial counterparty: Ulrich, identified as a represented manufacturer; channel: independent JETRO report published on jetro.go.jp; earliest independently dated observation: 2021; latest observation: Gil Medical’s own active partner listing retrieved in October 2026; status: continuing public commercial representation, with latest shipment and contract dates unknown; intended audience: medical-equipment purchasers and distributors. ⁹

Acting entity: Gil Medical Group; beneficiary or represented manufacturer: Ulrich; channel: Gil Medical’s partner page on gilmedical.co.il; earliest date of the individual page unknown; latest observation: 28 October 2026; status: currently published listing; exact beginning, contractual duration and transaction history unknown; audience: potential Israeli medical-equipment customers. ⁸

Acting entity: Gil Medical Group; represented manufacturer: Ulrich; product category: spinal implants and fixation; channel: gilmedical.co.il orthopedic catalogue; earliest publication date unknown; latest observation: 28 October 2026; status: currently advertised; actual inventory and shipment dates unknown; audience: orthopedic equipment purchasers. ¹⁰

Acting entity: Gil Medical Ltd; customer category: Israeli Ministry of Defense and private hospitals; channel: JETRO’s 2021 company profile on jetro.go.jp; earliest and latest dated evidence of this customer representation: 2021; status in October 2026: unknown; exact products, monetary value and individual supply contracts unknown. ⁹

Internal Governance, Content & Retail Policies

Employee relations

The manufacturer’s published compliance framework describes a confidential whistleblower reporting system intended to protect whistleblowers and affected persons. ¹²

No public evidence identified in the reviewed company governance and news materials of disciplinary action against employees for pro-Palestinian speech, political symbols, participation in solidarity campaigns or Israel-Palestine-related union activity. ¹²

Platform and editorial policies

The company describes its principal business as the development, manufacturing and sale of spinal surgery systems and radiology equipment, without identifying a public social-media or political-content platform in its corporate business description. ¹³

No public evidence identified in the reviewed corporate materials of algorithmic suppression of Palestinian content, Gaza-related editorial moderation or an Israel-Palestine-related platform enforcement controversy attributable to ulrich GmbH & Co. KG. ¹³

Retail and supply-chain policies

The manufacturer emphasizes German development and production and describes an international distributor network. ³

Gil Medical advertises Ulrich orthopedic products to the Israeli market, but the reviewed catalogue does not identify settlement-origin products, settlement-specific labeling or a politically differentiated retail classification; no public evidence identified. ¹⁰

Governance and policy act record

Acting entity: ulrich GmbH & Co. KG; beneficiaries: employees and affected persons eligible to use its reporting mechanism; channel: publicly available compliance page on ulrichmedical.com; earliest introduction date unknown; latest observation: October 2026; status: publicly advertised as active; reporting language concerns general compliance, with no published Israel-Palestine-specific enforcement finding identified on the reviewed page. ¹²

Brand Heritage & State Partnerships

Brand heritage

Heinrich C. Ulrich established the medical technology company in Ulm in 1912, with early activity focused on surgical instruments and an orthopedic workshop. ¹⁴

The company’s published history identifies subsequent development of contrast-media injectors and spinal implants as milestones in its medical technology business. ¹⁴

The company markets its brand through German engineering, product quality, medical innovation and healthcare applications, rather than an expressly stated military or state-security heritage. ³

Institutional relationships and sponsorships

On 25 September 2025, the company publicly announced a four-year sponsorship of the German women’s national sitting volleyball team, including financial assistance and company social-media support. ⁵

On 6 October 2026, ulrich GmbH & Co. KG reported its role as presenting partner at Nursing Day alongside ratiopharm ulm and University Hospital Ulm. ⁶

On 21 May 2025, the company reported hosting an international Spine Academy Meeting involving 40 surgeons and 17 speakers between 13 and 15 May 2025. ¹⁵

State-linked political sponsorship

No public evidence identified in the reviewed manufacturer news and institutional partnership announcements of sponsorship of an Israeli government public-relations campaign, military heritage programme, settlement event or pro-settlement cultural initiative. ⁴

Institutional act records

Acting entity: ulrich GmbH & Co. KG; beneficiary: German women’s national sitting volleyball team; channel: corporate website announcement and company social-media support; earliest dated announcement: 25 September 2025; declared duration: four years; status: publicly announced as a continuing sponsorship; financial amount undisclosed. ⁵

Acting entity: ulrich GmbH & Co. KG; counterparts: ratiopharm ulm and University Hospital Ulm; beneficiary: nursing professionals; channel: public sporting-event sponsorship and corporate announcement; event date: 30 September 2026; announcement date: 6 October 2026; event status: completed; broader marketing-partnership status: announced for the 2026–2027 season. ⁶

Acting entity: ulrich GmbH & Co. KG; beneficiaries: participating spinal surgeons and medical professionals; channel: professional training event at the company, described on ulrichmedical.com; event dates: 13–15 May 2025; publication date: 21 May 2025; event status: completed; participation: 40 surgeons and 17 speakers. ¹⁵

Lobbying, Advocacy, Financing & Logistics

Political lobbying

The manufacturer’s publicly available compliance, company information and news pages do not disclose an Israel-Palestine-specific lobbying programme, anti-BDS campaign or political-action committee; no public evidence identified in the reviewed records. ¹²

Financial contributions

The 2025 sports sponsorship announcement confirms financial support for the German women’s national sitting volleyball team but does not identify an Israeli state, military, settlement or political beneficiary. ⁵

No public evidence identified in the reviewed corporate announcements of donations by ulrich GmbH & Co. KG to the IDF, Friends of the IDF, JNF/KKL, Israeli reservist funds, settlement organizations or military-welfare institutions. ⁴

Israeli intermediary and potential defense procurement

Gil Medical Ltd’s 2021 JETRO profile simultaneously identifies Ulrich among represented medical-equipment manufacturers and the Ministry of Defense among Gil Medical’s principal customers. ⁹

The document provides no product-level mapping between those manufacturers and customers, and therefore does not establish that Ulrich equipment was purchased for military use. ⁹

Crisis logistics and resource mobilization

No public evidence identified in the reviewed manufacturer and Israeli intermediary publications of Ulrich-directed wartime logistics, donated medical equipment for Israeli military use, preferential reservist support or no-charge services supplied to a military organization. ¹⁶

Commercial agreements outside the identified Israeli distributor relationship

On 28 November 2022, ulrich GmbH & Co. KG announced an agreement under which GE Healthcare would distribute a GE-branded CT motion injector manufactured by Ulrich in the United States. ¹⁷

On 24 November 2023, ulrich GmbH & Co. KG announced an agreement for Bracco Imaging S.p.A. to distribute an Ulrich-manufactured MRI contrast-media injector under the Bracco brand in the United States. ¹⁸

Neither announcement establishes an Israeli military, settlement or political-advocacy beneficiary. ¹⁷

Financing and commercial act records

Acting entity: ulrich GmbH & Co. KG; recipient: German women’s national sitting volleyball team; channel: direct sponsorship publicly disclosed on ulrichmedical.com; announcement: 25 September 2025; duration announced: four years; monetary value not disclosed; status: intended to continue toward the 2028 Paralympics. ⁵

Acting entities: ulrich GmbH & Co. KG and GE Healthcare; beneficiary: US medical-equipment distribution market; channel: commercial distribution agreement disclosed on ulrichmedical.com; announcement: 28 November 2022; subsequent termination or renewal date unknown; geographic scope: United States. ¹⁷

Acting entities: ulrich GmbH & Co. KG and Bracco Imaging S.p.A.; beneficiary: US diagnostic-imaging market; channel: commercial agreement disclosed on ulrichmedical.com; announcement: 24 November 2023; subsequent termination or renewal date unknown; geographic scope: United States. ¹⁸

Acting entity: Gil Medical Ltd; documented customer category: Israeli Ministry of Defense; channel: independent JETRO company profile; observation year: 2021; latest contractual status unknown; product-level relationship with Ulrich unestablished. ⁹

Ulrich Medical’s official website dates its announcement of the Bracco Imaging S.p.A. MRI-injector distribution agreement to 21 November 2023, as confirmed by both its English-language announcement and corporate news archive. However, the manufacturer’s original English-language press-release PDF is explicitly dated 24 November 2023. The existing audit’s statements under “Commercial agreements outside the identified Israeli distributor relationship” and “Financing and commercial act records” therefore correctly reflect the PDF’s date but require qualification: 21 November 2023 is the date displayed on the corporate website, while 24 November 2023 is the date printed on the manufacturer’s press-release document. Bracco’s separate corporate announcement is dated 22 November 2023. These records establish differing publication dates without establishing the agreement’s exact signing date.^{19, 20, 21}

Corporate Structure & Primary Mission

Legal structure

The company’s official imprint identifies ulrich GmbH & Co. KG as the operating entity and ulrich Verwaltungs GmbH as its personally liable corporate partner. ²

The same imprint names Christoph Ulrich as managing partner, Friedrich von Rechteren as chief executive and Gordon Bittig as chief financial officer. ²

The company’s US subsidiary identifies the enterprise as privately held and family-owned. ²²

Foundational mandate

The manufacturer traces its history to a surgical-instrument and orthopedic workshop founded by Heinrich C. Ulrich in 1912. ¹⁴

Its current published mission describes healthcare innovation, medical-device development, manufacturing and support for medical professionals. ³

No explicitly geopolitical mandate, Israeli state ownership interest or Israeli state-held veto right is identified in the reviewed corporate structure and mission disclosures; no public evidence identified. ²

Integrated group entities

ulrich medical USA, Inc. was established in 2006 and now identifies its US corporate headquarters as Plano, Texas. ²²

ulrich medical France SAS was established in 2017 to support direct medical-device distribution in France. ¹⁴

The company’s historical account identifies October 2024 as the beginning of direct Spanish distribution through its new subsidiary. ¹⁴

The corporate news archive describes the group as comprising the German parent and subsidiaries in France, Spain and the United States. ²³

Equity holders

The company describes itself as family-owned, with Christoph Ulrich occupying the position of managing partner, but the retrieved corporate materials do not specify individual shareholding percentages. ²²

No named shareholder holding at least 10% of the equity was independently established from the reviewed company disclosures; no public evidence identified of an exact ownership-percentage breakdown. ²

Structure and ownership act records

Acting entity: ulrich GmbH & Co. KG; corporate partner: ulrich Verwaltungs GmbH; channel: the manufacturer’s official legal imprint; date of formation of the corporate partner unknown from the page; latest observation: October 2026; status: currently identified as the personally liable partner. ²

Acting entity: ulrich GmbH & Co. KG; subsidiary: ulrich medical USA, Inc.; channel: the manufacturer’s corporate history and US subsidiary website; establishment: 2006 [pre-2020]; latest observation: October 2026; status: current operating subsidiary. ²²

Acting entity: ulrich GmbH & Co. KG; subsidiary: ulrich medical France SAS; channel: corporate history; establishment: 2017 [pre-2020]; latest observation: October 2026 corporate locations disclosure; status: current subsidiary. ¹⁴

Acting entity: ulrich GmbH & Co. KG; subsidiary: ulrich medical España; channel: corporate history and locations disclosure; establishment: October 2024; latest observation: October 2026; status: current subsidiary. ⁷

Ulrich Medical’s official announcement of 24 September 2024 explicitly identifies 10 July 2024 as the establishment date of ulrich medical España and 1 October 2024 as the commencement of direct sales through that subsidiary. Its Spanish-language announcement independently confirms both dates. The existing audit’s statement that direct Spanish distribution began in October 2024 is therefore confirmed. However, the separate statement under “Structure and ownership act records” identifying October 2024 as the subsidiary’s establishment date requires correction to 10 July 2024. The subsidiary’s legal establishment preceded its direct commercial distribution operations by approximately three months.^{24, 25}

Executive & Leadership Footprint

Current controlling and senior leadership

The company’s management page identifies Christoph Ulrich as managing partner, Friedrich von Rechteren as CEO and chairman, and Gordon Bittig as CFO. ²⁶

The company states that Friedrich von Rechteren became CEO and chairman on 1 June 2025, succeeding Klaus Kiesel. ²⁶

The company’s January 2026 announcement identifies Gordon Bittig as CFO and managing director and describes him, Christoph Ulrich and Friedrich von Rechteren as the new leadership team. ²⁷

The company’s management page additionally identifies Sven Erdmann with technology and regulation, Steffen Kölsch with operations and quality management, and Cornelia Schweizer with sales and marketing. ²⁶

Founder and historical family leadership

Heinrich C. Ulrich founded the company in 1912; his son Max Ulrich joined in 1925; Heiner Ulrich joined in 1967 and subsequently handed management to Christoph Ulrich in 2009. ¹⁴

Christoph Ulrich’s continued managing-partner position is confirmed by the 2026 management disclosure. ²⁷

Named-entity search record

• ulrich GmbH & Co. KG - target German operating company; searches covered Israel-Palestine statements, lobbying, donations, settlements, military procurement and boycott activity; Israeli distributor representation identified through Gil Medical; no verified political-financing act identified. ⁸
• ulrich Verwaltungs GmbH - personally liable corporate partner; searched for Israel-related political financing and affiliations; searched, none found in the reviewed public disclosures. ²
• Christoph Ulrich - managing partner and fourth-generation family executive; searches covered Israel, settlements, FIDF, JNF, defense investments and public advocacy; a documented public statement concerns the 2025 sitting-volleyball sponsorship; no Israel-Palestine political act identified. ⁵
• Friedrich von Rechteren - CEO and chairman from June 2025; searches covered Israel-Palestine statements, political donations, defense affiliations and settlements; a 2026 statement concerning appreciation for nursing staff was identified; no Israel-Palestine political act identified. ⁶
• Gordon Bittig - CFO and managing director; searches covered regional political financing, advocacy, military and settlement affiliations; searched, none found in the reviewed leadership materials. ²⁷
• Klaus Kiesel - former CEO; searches covered Israel-Palestine advocacy, donations and military affiliations; documented statements concern corporate growth and commercial distribution; no Israel-Palestine political act identified. ²⁸
• Heinrich C. Ulrich - founder; historical identity verified through company records; searches for relevant geopolitical or institutional affiliations produced no identified result. ¹⁴
• Max Ulrich - historical family principal; historical identity verified; searches for relevant geopolitical affiliations produced no identified result. ¹⁴
• Heiner Ulrich - former senior executive; historical management role verified; searches for Israel-related financing and public advocacy produced no identified result. ¹⁴
• Sven Erdmann - technology and regulatory executive; searches covered defense-sector and settlement-related affiliations; searched, none found in the reviewed leadership materials. ²⁶
• Steffen Kölsch - operations and quality executive; searches covered defense-sector and settlement-related affiliations; searched, none found in the reviewed leadership materials. ²⁶
• Cornelia Schweizer - sales and marketing executive; searches covered Israel-related advocacy, military affiliations and philanthropy; identified commercial statements concern US healthcare distribution; no Israel-Palestine political act identified. ²⁹
• ulrich medical USA, Inc. - US subsidiary; searches covered lobbying, PAC contributions, Israel-Palestine advocacy and military donations; searched, none found in the reviewed subsidiary materials. ²²
• ulrich medical France SAS - French subsidiary; searches covered regional political advocacy, financing and settlement connections; searched, none found in the reviewed corporate records. ⁷
• ulrich medical España - Spanish subsidiary established in 2024; searches covered regional political activity and financing; searched, none found in the reviewed corporate records. ⁷
• Gil Medical Ltd - independently identified Israeli commercial intermediary; searches covered military customers, settlement locations and political links; the 2021 JETRO report identifies the Ministry of Defense among its principal customers without specifying Ulrich products. ⁹

Unidentified beneficial owners

The reviewed official disclosures do not provide an exhaustive beneficial-ownership list, individual ownership percentages or sufficient information to name every holder of at least 10% of the equity. ²

Personal financing and political advocacy

No public evidence identified in the reviewed company leadership and public announcement materials of donations by the named Ulrich executives to FIDF, JNF/KKL, Israeli settlement organizations, Israeli military-welfare funds or Israel-Palestine lobbying organizations. ²⁶

No public evidence identified in the reviewed executive biographies or statements of board membership in AIPAC, CFI, a settlement advocacy organization or an Israel-Palestine political pressure group. ²⁶

Public leadership communications

In a press release dated 25 September 2025, Christoph Ulrich described the company’s sponsorship of the German women’s national sitting volleyball team as supporting inclusion and equal opportunities. ⁵

In a press release dated 6 October 2026, Friedrich von Rechteren discussed the importance of healthcare professionals and their contribution to patient care. ⁶

In the company’s 22 January 2025 revenue announcement, then CEO Klaus Kiesel discussed long-term business strategy and Friedrich von Rechteren discussed the relationship between international commercial growth and German manufacturing. ²⁸

Executive act records

Acting individual: Christoph Ulrich; capacity: managing partner of ulrich GmbH & Co. KG; communication recipient and beneficiary: German women’s national sitting volleyball team; channel: company press release on ulrichmedical.com; first dated observation: 25 September 2025; latest observed availability: October 2026; communication status: published and retained; audience: public corporate website readership; audience size unknown. ⁵

Acting individual: Friedrich von Rechteren; capacity: CEO of ulrich GmbH & Co. KG; communication beneficiaries: healthcare professionals associated with Nursing Day; channel: company press release on ulrichmedical.com; dated publication: 6 October 2026; latest observed availability: October 2026; communication status: published and retained; audience: event participants and public website readership; audience size unknown. ⁶

Acting individual: Klaus Kiesel; capacity at the time: CEO of ulrich GmbH & Co. KG; communication beneficiary: company stakeholders and medical-device customers; channel: corporate revenue announcement on ulrichmedical.com; dated publication: 22 January 2025; subsequent executive succession: 1 June 2025; audience: corporate stakeholders and public readers; exact audience size unknown. ²⁸